<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=euc-jp" />
<meta http-equiv="content-style-type" content="text/css" />
<meta http-equiv="content-script-type" content="text/javascript" />

<title>Past Issues | YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;</title>

<meta name="Description" content="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" />
<meta name="Keywords" content="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" />
<meta http-equiv="imagetoolbar" content="no" />
<link rel="stylesheet" type="text/css" media="all" href="../../css/style.css" />
<link rel="stylesheet" type="text/css" media="all" href="../../css/en.css" />
<script type="text/javascript" src="../../js/jquery.js"></script>
<script type="text/javascript" src="../../js/jquery.function.js"></script>
</head>

<body class="page">
<div id="container">

<div id="header">
<p id="siteLogo"><a href="../../en.html"><img src="../../img/common/logo_en.gif" alt="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" width="437" height="28" /></a></p>
<p id="tagline"> YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot; is the private medical supply supervisory system.</p>
<div id="navUtility">
<ul>
<li><a href="../sitemap.html">Sitemap</a></li>
<li><a href="../../index.html">Japanese</a></li>
</ul>
<!-- /#navUtility --></div>
<div id="searchArea">
<form name="form1" action="http://www.yakugai.gr.jp/en/search.php" method="post">
<p><input id="searchInput" name="keyword" type="text" />&nbsp;<input value="Search" type="submit" /></p>
</form>
<!-- /#searchInput --></div>
<!-- /#header --></div>

<div id="nav">
<ul>
<li id="navHome"><a href="../../en.html">Home</a></li>
<li><a href="../about.html">About Us</a></li>
<li><a href="../activity.html">Activities</a></li>
<li class="current"><a href="../inve.html">Past Issues</a></li>
<li><a href="../about/about_links.html">Links</a></li>
</ul>
<!-- /#nav --></div>

<div class="inve" id="pageTitle">
<h1>Past Issues</h1>
<!-- /#pageTitle --></div>

<div id="topicPath">
<ol>
<li id="topicPathHome"><a href="../../en.html">Home</a></li>
<li>Past Issues</li>
</ol>
<!-- /#topicPath --></div>

<div id="contents">
<div id="main">
<h2>Adoair Diskus¡Êfulticasone propionate/salmeterol xinafoate dry-powder inhaler¡Ë</h2>

<div id="inveArticle"><p>
Adoair Diskus (a combination of fulticasone propionate and salmeterol xinafoate taken by inhalation) was used by GlaxoSmithKline K.K. in April 2004 for the long-term maintenance treatment of asthma in adults and children. We opposed its approval and issued a letter of request to the Ministry of Health, Labor and Welfare (MHLW) and GSK in May 2005.<br />
<br />
 Our reasons were as follows: <br />
<br />
1)	One component, Fulticasone propionate, is reported to be linked to the risk of acute adrenal failure because it easily accumulates in organs.<br />
<br />
2)	Salmeterol xinafoate, another component, is a long-acting ¦Â-stimulant (not¦Â2-selective). It should not be used regularly, because it may increase the risk of sudden death, which has already been proved in RCT and several large epidemiological investigations.<br />
<br />
3)	A combination of the above components for long-term treatment may increase the risk of harm. It is difficult to determine the best dose and judge when the right time to change the treatment process is. It is recommended that Adoair Discus combined with 50¦Ìg of salmeterol xinafoate and 500¦Ìg of fulticasone be inhaled twice a day.<br />
This means that the total daily dose of fulticsone is 1000ug, which is more than the highest dose of 800¦Ìg/day of Fultide (single component of fulticsone), and the risk of adrenal suppression increases.<br />
<br />
Adoair was approved two years after our proposition in April 2007. The pediatric indication was withdrawn by GSK, and the Pharmaceutical Affairs and Food Sanitation Council concluded that Adoair should be used carefully on adult patients in a more serious condition.<br />
<br />
The MHLW also ordered a post- approval study on the safety and effectiveness of long-term use as a condition for approval. <br />
<br />
However, in January 2009, Adoair 100 Diskus(fulticasone100¦Ìg /salmeterol25¦Ìg) and 50Air(fulticasone50¦Ìg /salmeterol25¦Ìg) were approved for use in the treatment of childhood asthma without substantial evidence of safety and efficacy when used in mild cases and children under 4 years old.<br />
<br />
We should disseminate this fact and act accordingly in order to prevent serious and fatal harm.<br />
<!-- /#inveArticle --></p></div>

<div class="sectionList" >
<h3>Topics</h3>
<ul class="ex">
<li class="person">YAKUGAI Ombudsperson</li>
<li class="tieup">Tie-up Group</li>
</ul>
<p>No Related Information</p><!-- /.sectionList -->
</div>
<!-- /#main --></div>

<div id="sub">
<h2>Table Of Contents</h2>
<div id="navSub">
<ul>
<li><a href="index.php.html#inveDrug">Drugs</a></li>
<li><a href="index.php.html#inveSystem">Systems</a></li>
</ul>
<!-- /#navSub --></div>
<!-- /#sub --></div>
<!-- /#contents --></div>

<div id="footer">
<p id="siteAdress">YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot; Tie-up group<br />
160-0022¡¡Tokyo Shinjuku Ward Shinjuku 1-14-4  AM building<br />
TEL : 03¡Ê3350¡Ë0607¡¡FAX : 03¡Ê5363¡Ë7080<br />
Mail : <a href="mailto:info@yakugai.gr.jp">&#105;&#110;&#102;o&#64;y&#97;&#107;u&#103;&#97;&#105;&#46;&#103;r.&#106;&#112;</a></p>

<div id="footerInner">
<ul id="navFooter">
<li><a href="../privacy.html">Privacy Policy</a></li>
</ul>
<p id="siteInfo">Our members have other regular jobs and volunteer their services free of charge. Our secretariat also serves as part-time basis, and we are currently in the process of facilitating the secretariat function. Therefore, please note that due to limited resources, we might not be able to respond to each inquiry on specific medicine. Thank you for your understanding.</p>
<p id="copyright"><img src="../../img/common/copyright.gif" alt="Copyright (c) YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;. all rights reserved." width="419" height="11" /></p>
<!-- /#footerInner --></div>

<!-- /#footer --></div>

<!-- /#container --></div>

<!-- google Analytics -->
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
try {
var pageTracker = _gat._getTracker("UA-11615542-1");
pageTracker._trackPageview();
} catch(err) {}
</script>
<!-- /google Analytics -->
<!-- nakanohito -->
<script LANGUAGE="Javascript">
<!--
var refer = document.referrer;
document.write("<a href='http://nakanohito.jp/'>");
document.write("<img src='http://nakanohito.jp/an/?u=202528&h=897479&w=48&guid=ON&t=&version=js&refer="+escape(parent.document.referrer)+"&url="+escape(parent.document.URL)+"' border='0' width='48' height='48' />");
document.write("</a>");
//-->
</script>
<noscript>
<img src="http://nakanohito.jp/an/?u=202528&h=897479&w=48&guid=ON&t=" width="48" height="48" alt="" border="0" />
</noscript>
<!-- nakanohito end -->

</body>
</html>
